Background Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small…
Read More
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced today that it will present a…
Read More
Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors…
Read More
BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
Read More
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019- Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today…
Read More
Hamilton, ON - Full Time Research Scientist - Chemistry Fusion Pharmaceuticals Inc. is a clinical stage radiopharmaceutical company developing Targeted…
Read More
